Currently Viewing:
The Academy of Managed Care Pharmacy (AMCP) 2018
Specialty Drug Pipeline Review Focuses on Competition, Cancer Drugs
April 24, 2018
Dr Robert Navarro Discusses Progress in Shift to Value-Based Care
April 24, 2018
Brian Litten Outlines How Medication Therapy Management Can Address Opioid Misuse
April 24, 2018
Who Decides What Value Looks Like in US Healthcare?
April 24, 2018
Dr Brandon Newman Discusses Payer, Academic Medical Center Collaboration
April 25, 2018
Currently Reading
Dr Aimee Tharaldson Discusses Key Market Trends in Specialty Pharmacy
April 25, 2018
Market Access Teams Face New Challenges in Pharma
April 25, 2018
Cardiologist Talks About Value of Monoclonal Antibody Evolocumab
April 26, 2018
Dr Somali Burgess on the Role of Patient-Reported Outcomes in Managed Care Pharmacy
April 26, 2018
Dr Tina Joseph Discusses Collaborative Practice Agreements Between Pharmacists, Physicians
April 26, 2018
Navigating the Rocky Waters to Value-Based Healthcare
April 26, 2018
Hemophilia: Treatment Landscape, Costs, and Disease Management
April 26, 2018
Dr Aimee Tharaldson on Recently Approved Specialty Drugs, Upcoming Approvals to Watch
May 05, 2018
Dr Calvin Knowlton Outlines Benefits Seen From Enhanced Medication Therapy Management
May 06, 2018
The Rise of Orphan Drugs for Rare Diseases
May 07, 2018
Dr Robert Navarro Foresees Unintended Consequences From Shift to Value-Based Care
May 12, 2018
Dr Kimberly Lenz: Identifying Patients Most at Risk For Substance Abuse
May 13, 2018
Brian Litten Outlines Challenges With Adopting Medication Therapy Management Services
May 17, 2018
Dr Tina Joseph Outlines Pharmacists' Role in Managing Chronic Diseases, Value-Based Care Models
May 19, 2018
Dr Calvin Knowlton on Innovative Practices in Enhanced Medication Therapy Management
May 20, 2018
Dr Ashley Pappas Discusses Collaboration Between Academic Centers and Payers
May 24, 2018
Dr Robert Navarro on Pharma Implementing Value, Best Practices for Value-Based Contracts
May 25, 2018
Drug Approvals That Dr Aimee Tharaldson Is Keeping an Eye on for 2019
May 27, 2018
Dr Kimberly Lenz on Implementing, Enforcing Appropriate Opioid Prescribing
June 04, 2018

Dr Aimee Tharaldson Discusses Key Market Trends in Specialty Pharmacy

There is a lot of competition in specialty pharmacy right now, said Aimee Tharaldson, PharmD, a senior clinical consultant in Emerging Therapeutics for Express Scripts.


There is a lot of competition in specialty pharmacy right now, said Aimee Tharaldson, PharmD, a senior clinical consultant in Emerging Therapeutics for Express Scripts.

Transcript

What are some current key market trends in specialty pharmacy?

The FDA is definitely approving a lot of specialty drugs. In 2017, they approved 36 new specialty medications, and that’s just the trend that we’ve been seeing. When you look at drug spend under the pharmacy benefit, specialty drugs right now account for about 41% of spend. But, by 2019, we’re expecting about half of spend is going to be on specialty medications. Even though less than 2% of people take specialty drugs, they cost, on average, $3000 per month; so, they’re very expensive. So, that’s definitely where the market is focused.

We’re seeing a lot of competition in the specialty space now, so that’s even affecting orphan conditions, several cancer conditions, as well as more common specialty therapy classes. So, that potentially will lead to more cost-saving opportunity over time. We have specialty drugs going generic, too, which could have an impact. We recently had Copaxone go generic with the 40 mg strength. Zytiga, Gilenya, are some near-term ones that are going to be facing generic competition in the near future. So, that helps with competition.

We also have the biosimilars. So far, the FDA has approved 9 biosimilar medications. Unfortunately, only 3 have been launched. But, in the near future we are going to have more. We could have biosimilars to Epogen, Procrit this year, additional filgrastim biosimilars, Neulasta biosimilars. That could all occur this year. Even a Rituxan, which could happen sometime this year or next. Eventually, we’re going to have several biosimilars to Humira, so that’s really going to increase the competition and bring down the costs in the market.

So, competition is the main one I think.

 
Copyright AJMC 2006-2019 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up